Tomonao Taira

Tomonao Taira

Auto-generated profile, based on publicly available information

Tomonao Taira

Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East , 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2024 in Pancreatology
Verified
Journal Article
Closed access
KIKanae Inoue
Kanae Inoue
KFKoh Fukushi
Koh Fukushi
SYShota Yamaguchi
Shota Yamaguchi
TTTomonao Taira
Tomonao Taira
TSTaro Shibuki
Taro Shibuki
MIMasafumi Ikeda
Masafumi Ikeda

20 March 2026 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
TTTomonao Taira
Tomonao Taira
TSTomoyuki Satake
Tomoyuki Satake
GIGo Igarashi
Go Igarashi
KIKanae Inoue
Kanae Inoue
TSTaro Shibuki
Taro Shibuki
MIMasafumi Ikeda
Masafumi Ikeda
Background: Pancreatic cancers other than pancreatic ductal adenocarcinoma (PDAC) are rare and heterogeneous, accounting for fewer than 5%–7% of all pancreatic cancers. These include acinar cell carcinoma, undifferentiated carcinoma, adenosquamous carcinoma, colloid carcinoma, neuroendocrine carcinoma (NEC), mixed neuroendocrine–non-neuroendocrine neoplasm (MiNEN), and invasive intraductal papillary mucinous carcinoma (IPMC). Optimal treatment strategies, including sequencing and later-line options, remain unclear. Although nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and l-leucovorin (LV) is effective in gemcitabine-refractory PDAC, its role in these rare subtypes is unknown. Methods: We retrospectively analyzed nine patients with one of these rare subtypes who received nal-IRI plus 5-FU and LV between June 2020 and November 2024. Efficacy and safety were evaluated. Results: The cohort included two cases each of IPMC and adenosquamous carcinoma, and one case each of colloid carcinoma, undifferentiated carcinoma, acinar cell carcinoma, NEC, and MiNEN. Partial responses were observed in four patients, including undifferentiated carcinoma, acinar cell carcinoma, NEC, and MiNEN, even among tumors refractory to gemcitabine- or platinum-based regimens. Disease control was achieved in seven patients (77.8%). The median progression-free survival was 6.8 months. Disease control exceeding 12 months was observed in three patients. Median overall survival from first-line therapy was not reached. Treatment-related toxicities were generally manageable, with neutropenia being the most common grade ≥ 3 adverse event. Conclusion: Nal-IRI plus 5-FU and LV showed antitumor activity and was tolerable among the nine patients analyzed in this study, suggesting it may be a therapeutic option in second- or later-line settings for rare pancreatic cancer.